HoldsUp

FoundMyFitness · 2022-04-28 · Rhonda Patrick (host), Dominic D'Agostino

Dr. Dominic D'Agostino on Developing a Well-Designed Ketogenic Diet and Harnessing Its Benefits

85 research-tied claims examined: 1 contradicted 5 overstated 6 context 60 supported 1 corroborated online 12 unverified

6

Needs context

0:58:05Dominic D'Agostinoneeds contextmoderate

Children maintained on ketogenic diets frequently develop carnitine deficiency due to high rates of fat oxidation.

"And then when you're on a ketogenic diet, you're oxidizing so much fat, you tend to be deficient in carnitine, and we see this like in kids that are on So I think carnitine is like really important." (said at 0:58:05)

A decline in free carnitine levels or mild hypocarnitinemia is observed in some children treated with ketogenic diets (typically around 15% to 25% of patients) because carnitine is consumed during increased fatty acid transport and oxidation. However, overt clinical or symptomatic carnitine deficiency is uncommon, total carnitine levels frequently stabilize over time, and carnitine depletion is strongly confounded by concurrent antiepileptic medications, particularly valproic acid. Universal deficiency does not occur, and routine carnitine supplementation is only required in a subset of patients.

0:57:10Dominic D'Agostinoneeds contextmoderate

The state of ketosis promotes the depletion of electrolytes from the body.

"electrolytes, which our bodies tend to deplete anyway when you're in a state of ketosis." (said at 0:57:10)

Ketosis promotes acute changes in renal electrolyte excretion—specifically an acute increase in urinary sodium excretion (natriuresis)—especially during the initiation phase of fasting or a ketogenic diet. However, this does not represent a uniform or sustained depletion of all electrolytes. In a randomized controlled crossover trial evaluating exogenous ketosis in healthy adults, ketone monoester supplementation acutely increased urinary sodium excretion, but urinary potassium excretion decreased, and total 24-hour urinary electrolyte excretion remained unchanged. A scoping review on ketogenic diet induction similarly noted that while transient electrolyte loss and symptoms ('keto-flu') are widely described physiologically, clinical trials documenting broad electrolyte depletion and the therapeutic efficacy of supplementation remain limited.

1:17:30Dominic D'Agostinoneeds contextvery low

In a study conducted at the USF Byrd Alzheimer's Institute, mice on an MCT-supplemented ketogenic diet ran approximately 30% longer and faster on a treadmill despite no robust changes in amyloid beta or tau pathology.

"in animal models, when you put them on a ketogenic diet, I think one of the first studies we did published at the Alzheimer's Institute at USF, the Byrd Alzheimer's, we didn't see a big robust effect on amyloid beta and tau, but we started the intervention after the pathology kicks in in these mouse models, uh double and triple knockout... but in our study, we didn't see any like major changes in tau or amyloid, but the mice like ran faster. They ran like 30% longer and faster on the treadmill" (said at 1:17:30)

The speaker is referring to a 2013 preclinical study conducted at the University of South Florida (Byrd Alzheimer's Institute) assessing a ketogenic diet in mouse models of Alzheimer's pathology (APP/PS1 and Tg4510 mice). The study confirmed that after 3 months of a ketogenic diet, mice showed significantly enhanced motor performance without significant changes in brain amyloid-beta or tau pathology. However, the motor testing was measured via accelerated rotarod performance rather than a treadmill, and the evidence is limited to animal models.

2:13:20Dominic D'Agostinoneeds contextvery low

Melanoma cell lines harboring the BRAF V600E mutation can use acetoacetate as an energy source and for biosynthetic reactions.

"So in particular, there's a melanoma cell line at least that has a BRAF V600E mutation, I believe, and those cancer cells have been shown to use acetoacetate as potentially an energy source, but also for biosynthetic reactions." (said at 2:13:20)

Preclinical studies demonstrate a strong link between BRAF V600E mutant melanoma and the ketone body acetoacetate, but through a distinct non-metabolic mechanism. Rather than utilizing acetoacetate primarily as an energy source or biosynthetic building block, BRAF V600E cells upregulate ketogenic enzymes (such as HMGCL and HMGCS1) to produce acetoacetate, which functions as a direct signaling metabolite. Acetoacetate selectively binds the BRAF V600E kinase and enhances its association with MEK1, promoting downstream MEK-ERK oncogenic signaling and tumor growth.

2:14:00Dominic D'Agostinoneeds contextmoderate

Hypoxia in an expanding tumor mass damages mitochondria, causing aggressive cancer cells to shift away from oxidative phosphorylation toward glycolysis relying on fermentable fuels like glucose and glutamine.

"And cancer cells that are more glycolytic and very sort of damaged in their respiration due to the hypoxia of expanding tumor mass—so as a tumor grows, it outstrips its ability to supply blood flow and oxygen to the tumor, so it becomes hypoxic, and that further damages the mitochondria, so it causes the tumor to be more glycolytic and less of the oxidative phosphorylation pathway." (said at 2:14:00)

As solid tumors expand, they frequently outstrip their vascular supply, creating hypoxic microenvironments. Under hypoxia, stabilization of hypoxia-inducible factors (primarily HIF-1α) downregulates mitochondrial oxidative phosphorylation (OXPHOS) and upregulates glycolysis and glucose/glutamine utilization. However, modern cancer biology clarifies that in most tumors, this metabolic shift is driven by active, reversible regulatory signaling (such as HIF-1-mediated induction of pyruvate dehydrogenase kinase 1 and suppression of mitochondrial biogenesis) rather than irreversible structural damage to the mitochondria, which typically remain functional.

2:12:25Dominic D'Agostinoneeds contextvery low

The addition of ketones to cancer cells decreases their proliferation via a ketone-induced reduction in the glycolytic enzyme hexokinase.

"even in the presence of consistent glucose, when we add ketones, there seems to be a decrease in proliferation, and we think that could be due to a ketone-induced decrease in hexokinase, which is a glycolytic enzyme." (said at 2:12:25)

In vitro laboratory studies demonstrate that exogenous ketone bodies (such as acetoacetate and beta-hydroxybutyrate) can suppress cell proliferation across various cancer cell lines. However, evidence directly establishing a ketone-induced reduction in hexokinase activity as the primary driver of this antiproliferative effect comes primarily from preliminary in vitro and preclinical models, and cancer cell responses to ketone bodies vary significantly depending on tumor type, genetics, and metabolic phenotype.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.